Opinion|Videos|October 7, 2024
Addressing Gaps in CKD, T2D, and CVD Guidelines
Key Takeaways
- Future guidelines may integrate emerging evidence and novel therapeutic strategies for CKD, T2D, and CVD management.
- Personalized treatment plans considering the interplay between CKD, T2D, and CVD could be emphasized.
Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How might future guideline updates address current gaps in the management of patients with CKD, T2D, and CVD?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
